Role of Lncrna Pvt1 in the Progression of Urological Cancers: Novel Insights Into Signaling Pathways and Clinical Opportunities Publisher Pubmed



Hashemi M^{1, 2} ; Gholamrezaie H¹ ; Ziyaei F^{1, 2} ; Asadi S^{1, 2} ; Naeini ZY^{1, 3} ; Salimian N^{1, 4} ; Enayat G¹ ; Sharifi N¹ ; Aliahmadi M¹ ; Rezaie YS¹ ; Khoushab S^{1, 2} ; Rahimzadeh P⁵ ; Miri H⁶ ; Abedi M⁷ Show All Authors
Source: Cellular Signalling Published:2025

Abstract

Urologic malignancies, encompassing cancers of the kidney, bladder, and prostate, represent approximately 25 % of all cancer cases. Recent advances have enhanced our understanding of PVT1's crucial functions. Long noncoding RNAs influence both the onset and development of cancer, as well as epigenetic alterations. Recent findings have focused on PVT1's mechanism of action across several malignancies, particularly urologic cancers. Understanding the various functions of PVT1 linked to cancer is necessary for the development of cancer detection and treatment when PVT1 is dysregulated. Furthermore, recent advancements in genomic and epigenetic research have elucidated the complex regulatory networks that control PVT1 expression. Comprehending the intricate role of PVT1 Understanding the complex function of PVT1 in urologic cancers has substantial clinical implications. Here, we summarize some of the most recent findings about the carcinogenic effects of PVT1 signaling pathways and the possible treatment strategies for urological malignancies that target these pathways. © 2025 Elsevier Inc.